Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
1 Penny Stock Where You Can Spend Less And Earn More

This tiny stock could soar more than 400%, according to Wall Street.

ATRA : 7.52 (-10.05%)
$SPX : 5,509.01 (+0.62%)
Atara Biotherapeutics: Q1 Earnings Snapshot

Atara Biotherapeutics: Q1 Earnings Snapshot

ATRA : 7.52 (-10.05%)
Atara Biotherapeutics: Q4 Earnings Snapshot

Atara Biotherapeutics: Q4 Earnings Snapshot

ATRA : 7.52 (-10.05%)
Atara Biotherapeutics: Q3 Earnings Snapshot

Atara Biotherapeutics: Q3 Earnings Snapshot

ATRA : 7.52 (-10.05%)
Atara Biotherapeutics: Q2 Earnings Snapshot

Atara Biotherapeutics: Q2 Earnings Snapshot

ATRA : 7.52 (-10.05%)
Atara Biotherapeutics: Q1 Earnings Snapshot

Atara Biotherapeutics: Q1 Earnings Snapshot

ATRA : 7.52 (-10.05%)
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 7.52 (-10.05%)
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 7.52 (-10.05%)
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 7.52 (-10.05%)
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 7.52 (-10.05%)

Barchart Exclusives

Is This Copper Mining Stock a Buy for Its Fat Dividend?
Southern Copper has a higher dividend yield compared to other copper mining companies. However, its valuations are also on the higher side, making a closer examination of the risk-reward necessary for prospective investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar